LTR Pharma Logo

LTR Pharma

LTR Pharma is a Clinical Stage Biopharmaceutical Company

Pioneering a novel intranasal technology – SPONTAN® – designed to treat Erectile Dysfunction in 10 minutes or less.

SPONTAN® (SDS-089) is a novel intranasal drug (PDE5) delivery platform for Erectile Dysfunction

About Erectile Dysfunction

Erectile Dysfunction (ED) is a condition in which you are unable to get or keep an erection firm enough for satisfactory sexual intercourse. ED can be a short-term or long-term problem.

Learn more

Our Solution

SPONTAN® provides on demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects

Learn More

Commercialisation

LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years

Learn more
322M

worldwide expected cases by 2025

10

minute effectiveness

$7.10B

projected global market value 2024

Global Market Need

ED is a serious and common medical problem with significant impacts to both physical and psychological health
ED has been identified as a major factor in relationship breakdown (20%). The worldwide prevalence doubled in the last 30 years and is expected to increase to 322 million in 2025.

Learn more

ON DEMAND
SOLUTION

LTR Pharma Couple

RAPID ONSET
ACTION

BRING BACK
SPONTANEITY

Clear commercial pathway to disrupt the established PDE5 market

Watch: Melissa Hadley Barrett explains SPONTAN® real-world data presented at APCC

2 October 2026

At the Asia-Pacific Prostate Cancer Conference (APCC) in Melbourne, Nurse Practitioner and Sexologist Melissa Hadley Barrett presented outcomes from 147 men who used SPONTAN nasal spray with a 93% response among men seeking greater convenience and spontaneity.  The retrospective study included 147 treatment-experienced men prescribed SPONTAN® in routine Australian clinical practice, making it

Read More »

Final Phase II report confirms SPONTAN® six-fold faster absorption

1 October 2026

LTR Pharma has received the final Clinical Study Report for its SPONTAN® Phase II pharmacokinetic study. The report completes the pharmacokinetic dataset agreed with the FDA for LTR Pharma’s planned U.S. 505(b)(2) submission. LTR’s SPONTAN® is a fast-acting intranasal spray for the treatment of erectile dysfunction, enabling an onset of

Read More »
LTR Pharma Expands Men's Health Platform Through Exclusive KYZATREX® Pilot Commercialisation Agreement in Australia

LTR Pharma Expands Men’s Health Platform Through Exclusive KYZATREX® Pilot Commercialisation Agreement in Australia 

1 September 2026

LTR Pharma has entered into an exclusive pilot commercialisation agreement with Marius Pharmaceuticals, a US pharmaceutical company focused on men’s health, to introduce Marius’ lead product, KYZATREX® (testosterone undecanoate oral capsules), in Australia. KYZATREX is FDA-approved and commercially available in the United States.   Strategic rationale  Testosterone deficiency affects energy, mood,

Read More »

Special Access Scheme

SPONTAN may be prescribed to eligible patients under the TGA’s Special Access Scheme. For more information, please register your details via our online form.

Register here

Receive our latest news and investor updates

By entering your email address you are agreeing to our privacy policy.